Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?
Authors
Keywords
-
Journal
Gastroenterology Report
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2019-10-26
DOI
10.1093/gastro/goz061
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Immunotherapy in colorectal cancer: rationale, challenges and potential
- (2019) Karuna Ganesh et al. Nature Reviews Gastroenterology & Hepatology
- Context Matters - Consensus Molecular Subtypes of Colorectal Cancer as Biomarkers for Clinical Trials
- (2019) E Fontana et al. ANNALS OF ONCOLOGY
- Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
- (2019) A B Schrock et al. ANNALS OF ONCOLOGY
- ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
- (2019) C Luchini et al. ANNALS OF ONCOLOGY
- INTRATUMORAL ADAPTIVE IMMUNOSUPPRESSION AND TYPE 17 IMMUNITY IN MISMATCH REPAIR PROFICIENT COLORECTAL TUMORS
- (2019) Nicolas J Llosa et al. CLINICAL CANCER RESEARCH
- A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC).
- (2019) Aparna Raj Parikh et al. JOURNAL OF CLINICAL ONCOLOGY
- CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC).
- (2019) Eric Xueyu Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.
- (2019) Manish A. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance)
- (2019) Heinz-Josef Lenz et al. JOURNAL OF CLINICAL ONCOLOGY
- Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies
- (2019) Dan Aderka et al. LANCET ONCOLOGY
- Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis
- (2019) Lianzhou Yang et al. OncoTargets and Therapy
- The Role of Checkpoint Inhibitors and Cytokines in Adoptive Cell-Based Cancer Immunotherapy with Genetically Modified T Cells
- (2019) P. M. Gershovich et al. BIOCHEMISTRY-MOSCOW
- Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
- (2019) Davide Ciardiello et al. CANCER TREATMENT REVIEWS
- Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
- (2019) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
- (2019) Cathy Eng et al. LANCET ONCOLOGY
- Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade
- (2019) Andrew Georgiadis et al. CLINICAL CANCER RESEARCH
- Inherited DNA-Repair Defects in Colorectal Cancer
- (2018) Saud H. AlDubayan et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer
- (2018) Rona Yaeger et al. CANCER CELL
- Update on Hereditary Colorectal Cancer: Improving the Clinical Utility of Multigene Panel Testing
- (2018) Marie Lorans et al. Clinical Colorectal Cancer
- The Impact of Microsatellite stability status in colorectal cancer
- (2018) Ruby Gupta et al. CURRENT PROBLEMS IN CANCER
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
- (2018) Franck Pagès et al. LANCET
- A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
- (2018) Daniela S. Thommen et al. NATURE MEDICINE
- DNA mismatch repair in cancer
- (2018) Marina Baretti et al. PHARMACOLOGY & THERAPEUTICS
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis
- (2018) Sean P. Pitroda et al. Nature Communications
- Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
- (2018) Muhammad Zubair Afzal et al. Journal for ImmunoTherapy of Cancer
- Combinations of Bevacizumab With Cancer Immunotherapy
- (2018) Daniel S. Chen et al. CANCER JOURNAL
- Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).
- (2018) Alexander Stein et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- LBA37_PRNeoadjuvant ipilimumab plus nivolumab in early stage colon cancer
- (2018) M Chalabi et al. ANNALS OF ONCOLOGY
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients
- (2018) Marc Van den Eynde et al. CANCER CELL
- Evolution of Metastases in Space and Time under Immune Selection
- (2018) Mihaela Angelova et al. CELL
- Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair–Deficient Colon Cancers: Implications for Prognosis
- (2018) Harry H. Yoon et al. CLINICAL CANCER RESEARCH
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
- (2018) J. Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- The prognostic value of immunoscore in patients with colorectal cancer: A systematic review and meta-analysis
- (2018) Guorui Sun et al. Cancer Medicine
- The potential and promise of IL-15 in immuno-oncogenic therapies
- (2017) Tanya O. Robinson et al. IMMUNOLOGY LETTERS
- Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival
- (2017) Bernhard Mlecnik et al. JNCI-Journal of the National Cancer Institute
- Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring aPOLEMutation
- (2017) Jun Gong et al. Journal of the National Comprehensive Cancer Network
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
- (2017) Bert H. O’Neil et al. PLoS One
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
- (2017) Priti S. Hegde et al. SEMINARS IN CANCER BIOLOGY
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival
- (2017) Bernhard Mlecnik et al. JNCI-Journal of the National Cancer Institute
- Increasing Tumor-Infiltrating T Cells through Inhibition of CXCL12 with NOX-A12 Synergizes with PD-1 Blockade
- (2017) Dirk Zboralski et al. Cancer Immunology Research
- Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance
- (2017) Marc Hennequart et al. Cancer Immunology Research
- Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer
- (2017) Rachel Pearlman et al. JAMA Oncology
- Emerging Opportunities and Challenges in Cancer Immunotherapy
- (2016) T. L. Whiteside et al. CLINICAL CANCER RESEARCH
- Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy
- (2016) Etienne Becht et al. CLINICAL CANCER RESEARCH
- PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
- (2016) Sara Gandini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Global patterns and trends in colorectal cancer incidence and mortality
- (2016) Melina Arnold et al. GUT
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
- (2016) Peter J.R. Ebert et al. IMMUNITY
- Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
- (2016) Bernhard Mlecnik et al. IMMUNITY
- The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis
- (2016) Pedro N Aguiar et al. Immunotherapy
- A pilot study of AMP-224, a PD-L2 Fc fusion protein, in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic colorectal cancer.
- (2016) Austin G. Duffy et al. JOURNAL OF CLINICAL ONCOLOGY
- Landscape of tumor-infiltrating T cell repertoire of human cancers
- (2016) Bo Li et al. NATURE GENETICS
- The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death
- (2016) Chiara Pozzi et al. NATURE MEDICINE
- The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
- (2016) Danny N. Khalil et al. Nature Reviews Clinical Oncology
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- PD-L1 expression in human cancers and its association with clinical outcomes
- (2016) Jinming Yu et al. OncoTargets and Therapy
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
- (2016) Valsamo Anagnostou et al. Cancer Discovery
- Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells
- (2016) E. J. Brea et al. Cancer Immunology Research
- Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone
- (2015) J Carrasco et al. BRITISH JOURNAL OF CANCER
- The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
- (2015) L. Liu et al. CLINICAL CANCER RESEARCH
- Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983
- (2015) Erik Tanis et al. EUROPEAN JOURNAL OF CANCER
- Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).
- (2015) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment andRASMutations in Colorectal Cancer
- (2015) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Integrated Akt/PKB Signaling in Immunomodulation and Its Potential Role in Cancer Immunotherapy
- (2015) G. Xue et al. JNCI-Journal of the National Cancer Institute
- Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
- (2015) Josep Tabernero et al. LANCET ONCOLOGY
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- The consensus molecular subtypes of colorectal cancer
- (2015) Justin Guinney et al. NATURE MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
- (2015) M. Vetizou et al. SCIENCE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy
- (2015) Mihaela Angelova et al. GENOME BIOLOGY
- Integrated Akt/PKB Signaling in Immunomodulation and Its Potential Role in Cancer Immunotherapy
- (2015) G. Xue et al. JNCI-Journal of the National Cancer Institute
- Tumoral Immune Resistance Mediated by Enzymes That Degrade Tryptophan
- (2015) N. van Baren et al. Cancer Immunology Research
- Human CD4+CD39+regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+exosomes or CD73+cells
- (2014) P. J. Schuler et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
- (2014) Alena Gros et al. JOURNAL OF CLINICAL INVESTIGATION
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
- (2014) Gregory T Motz et al. NATURE MEDICINE
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
- (2014) Nicolas J. Llosa et al. Cancer Discovery
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
- (2013) Jérôme Galon et al. JOURNAL OF PATHOLOGY
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
- (2013) N. Iida et al. SCIENCE
- Cancer Genome Landscapes
- (2013) B. Vogelstein et al. SCIENCE
- The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
- (2013) S. Viaud et al. SCIENCE
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy
- (2012) L. van de Laar et al. BLOOD
- Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
- (2012) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- Amino acid catabolism: a pivotal regulator of innate and adaptive immunity
- (2012) Tracy L. McGaha et al. IMMUNOLOGICAL REVIEWS
- Radiation Therapy to Convert the Tumor Into an In Situ Vaccine
- (2012) Silvia C. Formenti et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer
- (2011) L Ferdinande et al. BRITISH JOURNAL OF CANCER
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Interleukin-15 biology and its therapeutic implications in cancer
- (2011) Jason C. Steel et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Cytokines in Cancer Immunotherapy
- (2011) Sylvia Lee et al. Cancers
- 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
- (2010) J. Vincent et al. CANCER RESEARCH
- Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
- (2010) B. C. Carthon et al. CLINICAL CANCER RESEARCH
- Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer
- (2010) Ki Y. Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutator phenotypes due to DNA replication infidelity
- (2010) Mercedes E. Arana et al. SEMINARS IN CANCER BIOLOGY
- Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
- (2008) M. Dechant et al. CANCER RESEARCH
- Immunogenic cancer cell death: a key-lock paradigm
- (2008) Antoine Tesniere et al. CURRENT OPINION IN IMMUNOLOGY
- Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
- (2008) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- How tumours escape mass destruction
- (2008) T J Stewart et al. ONCOGENE
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
- (2008) F. S. Hodi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now